Venture Capital is an important pillar of corporate financing. In addition to private investors, a number of institutional investors play a substantial role in helping Antisense Pharma develop effective drugs for the treatment of cancer and other as yet incurable diseases. Antisense Pharma has secured investment from MIG Fonds, S-Refit AG, Global Asset Fund, Global Chance Fund, Technologie Beteiligungs­gesellschaft mbH tbg (since 2002 part of the kfw Mittelstandsbank), Technologie Beteiligungsfonds Bayern GmbH & Co. KG (stock of Bayern Kapital) and GA Beteiligungs GmbH.